Virus-like particles (VLPs) are nanoscale multimers self-assembled from viral structural proteins. Devoid of viral genomes and thus non-infectious, they hold tremendous potential in vaccine development, drug delivery, gene editing and other fields. VLPs can display native antigens and exert an intrinsic self-adjuvant effect; meanwhile, they exhibit superior biocompatibility compared with synthetic delivery vectors, rendering them a high-profile research frontier in biopharmaceuticals.
VLPs can be produced at scale via diverse host systems including microorganisms, plant and animal cells. Nevertheless, downstream purification remains the core bottleneck restricting their industrial translation. Distinct from conventional monomeric proteins, VLPs feature large particle sizes, intricate architectures, and high susceptibility to aggregation and degradation. Coupled with abundant host-derived impurities, substantial product heterogeneity and the absence of universal purification workflows, process development for VLPs poses formidable technical challenges. Accordingly, a customized purification engineering framework oriented toward critical quality attributes (CQAs) must be established by striking a balance among structural integrity, purity and biosafety, tailored to specific expression systems and product characteristics. This paper systematically elaborates a rigorous integrated downstream purification framework for VLPs built upon CQAs, following the sequential unit operations of bioprocessing, to address this sophisticated and engineering-intensive challenge.
1. Clarification
Clarification serves as the primary upstream barrier in VLP downstream workflows, with the core objective of removing cell debris and coarse particulate contaminants to lay a solid foundation for high-resolution polishing chromatography. Clarification performance directly governs process robustness and product recovery; suboptimal clarification triggers membrane fouling and premature degradation of chromatographic resin performance.
Process design is dictated by the subcellular localization of VLPs. Intracellularly expressed VLPs necessitate cell lysis upfront: high-pressure homogenization is the dominant method for microbial hosts, whereas mild chemical lysis is preferred for mammalian and insect cell cultures. Protease inhibitors are supplemented throughout lysis to mitigate proteolytic degradation of target VLPs.
Industrial clarification is predominantly implemented via two technical routes: centrifugation and depth filtration, with depth filtration progressively displacing centrifugation as the mainstream manufacturing choice. Depth filtration integrates size exclusion, electrostatic adsorption and hydrophobic interaction. Filter media embedded with filter aids and charged resin composites efficiently eliminate host cell proteins (HCPs), host cell DNA (HCD) and endotoxins in a single step.
Nuclease digestion represents an indispensable auxiliary treatment post-clarification. Nucleases fragment residual high-molecular-weight host DNA into short oligonucleotides, reducing feedstock viscosity and eliminating interferences with subsequent chromatographic separation. The synergistic combination of clarification and nuclease digestion generates a clean, homogeneous feed stream, substantially enhancing manufacturing consistency and reproducibility.
2. Ultrafiltration/Diafiltration (UF/DF)
Ultrafiltration/diafiltration constitutes an integrated and pivotal unit operation in VLP downstream processing. Leveraging size sieving across defined molecular weight cutoff (MWCO) membranes, UF/DF achieves three core functions: product concentration, buffer exchange and partial impurity clearance. Within the full purification cascade, UF/DF acts either as a front-end volume reduction step to alleviate loading pressure on downstream chromatography, or as a central process hub to precisely modulate solution environments for controlled disassembly and reassembly of VLP subunits.
Technically, ultrafiltration membranes feature an asymmetric structure, where separation performance is determined by a thin, dense selective skin layer. Common industrial membrane materials include polyethersulfone (PES), regenerated cellulose and polyvinylidene difluoride (PVDF), manufactured as flat-sheet membrane cassettes or hollow-fiber modules. Given that VLP hydrodynamic diameters far exceed those of HCPs, HCD and residual chemical additives, rational MWCO selection enables selective retention of intact VLPs while permeating small-molecule impurities. Further tuning of solution ionic strength improves impurity clearance efficiency, delivering feed material of elevated purity for subsequent polishing steps.
Nevertheless, fluid shear stress represents a critical risk factor during UF/DF execution. As delicate supramolecular nanostructures, VLPs are highly sensitive to environmental perturbations. Improper operation under high recirculation shear readily induces particle aggregation, morphological deformation and irreversible loss of biological functionality. To reconcile separation throughput with structural preservation, systematic process screening is mandatory, covering membrane material selection, module geometry (hollow-fiber cartridges deliver smoother flow paths and markedly lower shear stress relative to flat cassettes), as well as precise control over transmembrane pressure and crossflow shear rate. Experimental data validate that low-shear operating conditions effectively preserve the structural and functional integrity of enveloped VLPs. Conversely, unmitigated shear damage may trigger irreversible particle aggregation even under mild ambient storage conditions. Therefore, UF/DF development is not merely a physical separation exercise, but a customized structural protection workflow optimized for the intrinsic biophysical properties of target VLPs.
3. Chromatography
High-resolution chromatographic techniques are indispensable for attaining high purity and full quality compliance of VLPs. Chromatography enables mild, high-efficiency separation by exploiting subtle disparities between VLPs and impurities in surface charge, hydrophobicity, hydrodynamic size and biological affinity, while maximally retaining VLP bioactivity. In industrial VLP purification workflows, orthogonal chromatographic modalities are combined to form a three-stage purification cascade: capture, intermediate purification and polishing.
Size-Exclusion Chromatography (SEC)
SEC separates species based on differences in hydrodynamic particle size. Owing to the substantially larger dimensions of fully assembled VLPs relative to unassembled protein monomers and oligomeric fragments, SEC achieves sharp resolution between intact VLPs and product-related impurities, rendering it exceptional for final polishing. However, SEC suffers from limited throughput, lengthy processing cycles and poor scalability, restricting its application primarily to analytical characterization or terminal polishing steps.
Ion-Exchange Chromatography (IEX)
Boasting superior resolution and operational flexibility, IEX stands as the most widely adopted core chromatographic platform for VLP purification. Separation relies on differential net surface charge between VLPs and contaminants. For instance, anion-exchange chromatography is routinely deployed to remove strongly anionic HCD; fine-tuning of mobile-phase pH and conductivity enables flexible operational modes, either flow-through collection of target VLPs or on-column capture of impurities. Beyond nucleic acid clearance, IEX demonstrates broad-spectrum capability in removing HCPs, extracellular vesicles and VLP aggregates, serving as an ideal bridging step between crude capture and high-purity polishing.
Hydrophobic Interaction Chromatography (HIC)
HIC serves as a complementary orthogonal tool when VLPs and co-eluting impurities exhibit nearly identical charge profiles. Ordered surface topology endows intact VLPs with markedly higher overall hydrophobicity compared with dissociated monomers or fragmented particles. Under high-salt loading conditions, VLPs adsorb to hydrophobic ligands immobilized on resin matrices while impurities elute in the flow-through fraction; target VLPs are subsequently recovered via stepwise reduction of mobile-phase ionic strength.
Affinity Chromatography
Affinity chromatography delivers the highest selectivity among all chromatographic modalities, driven by specific biomolecular recognition mechanisms such as antigen–antibody and receptor–ligand interactions. Heparin affinity chromatography, for example, selectively captures VLPs displaying cognate surface binding domains, facilitating efficient separation from unrelated contaminants. Despite outstanding purification fold, affinity resins exhibit strict product specificity. Genetic fusion of affinity tags to VLP subunits is sometimes adopted to simplify downstream capture, yet this strategy requires rigorous risk assessment regarding potential impairments to VLP self-assembly and biological potency introduced by genetic modification.
Mixed-Mode Chromatography
The rapid advancement of mixed-mode chromatography provides a powerful solution for challenging separation scenarios. Single resin ligands integrate multiple interactive forces including electrostatic attraction, hydrophobic interaction and hydrogen bonding, enabling simultaneous clearance of recalcitrant impurities with overlapping size or charge properties matching VLPs. Amid the expanding diversity of VLP pipeline products, this multi-modal separation technology is poised to occupy an increasingly central role in advanced polishing workflows.
4. Disassembly and Reassembly
A pervasive technical hurdle in VLP manufacturing stems from endogenous encapsulation contaminants: host proteins, nucleic acids and lipids trapped within the internal cavity during particle assembly. Physically sequestered inside intact VLPs, these impurities evade conventional separation tools including chromatography and ultrafiltration, giving rise to the disassembly–reassembly purification strategy.
The core principle of this process follows a “break-and-reconstruct” paradigm. Controlled modulation of pH, ionic strength, or supplementation of reducing agents triggers reversible disassembly of intact VLPs into constituent protein subunits, fully releasing encapsulated internal impurities. Liberated contaminants are subsequently eliminated via orthogonal chromatography or tangential flow filtration, followed by buffer reconstitution under optimized physicochemical conditions to drive spontaneous subunit self-assembly into purified, homogeneous VLPs.
This workflow delivers dual advantages: comprehensive removal of endogenous encapsulated impurities to drastically elevate product purity, and effective mitigation of high-molecular-weight aggregates prevalent in heterologous expression systems, yielding particles with narrow monodisperse size distribution. For multi-layered complex VLPs, disassembly and reassembly further rectify structural assembly defects, improving the integrity and long-term stability of final drug substance.
Nevertheless, disassembly–reassembly represents an extremely precise and technically demanding bioprocess, whose success hinges entirely on meticulous control of assembly/disassembly driving forces. Dissociated subunits expose extensive hydrophobic interfaces; inadequate tuning of solution parameters readily induces irreversible non-specific aggregation, completely abolishing the self-assembly capacity of protein monomers. Therefore, exhaustive screening and delicate balancing of solvent composition, temperature, ionic strength and chemical additive concentrations are mandatory during process development. While this strategy is currently applicable mainly to non-enveloped VLPs, deepening mechanistic insights into protein supramolecular assembly will propel this root-cause particle purification technology into a core manufacturing pillar for high-quality biotherapeutics.
5. Buffer Management in Downstream Purification
Buffer design within VLP downstream workflows extends far beyond routine formulation work, functioning as a core engineering lever to safeguard supramolecular structural integrity and biological functionality across all unit operations. VLP stability is governed by a delicate equilibrium of multiple physicochemical forces, including electrostatic repulsion, hydrophobic interactions, inter-subunit bonding and enveloped membrane integrity. Accordingly, buffer development must shift from empirical trial-and-error to systematic optimization grounded in fundamental biochemical principles.
Key design considerations include: pH-dependent protein ionization and conformational stability; ionic strength and counterion-specific modulation of non-specific intermolecular interactions; and supplementation of surfactants, saccharides and polyols as stabilizers to enhance interfacial tolerance and thermal resilience of VLPs. The optimization workflow centers on identifying dominant failure modes of target particles under process stresses such as pH drift, conductivity shifts, mechanical shear and freeze–thaw cycling. Orthogonal characterization tools including dynamic light scattering (DLS), transmission electron microscopy (TEM) and biological potency assays enable real-time detection of particle aggregation, degradation and assembly loss. This stress-testing-oriented characterization framework is critical, as VLP stability manifests dynamically across variable solution environments, and single-point condition testing fails to reflect real-process performance.
Buffer optimization must be implemented throughout the entire purification cascade, rather than limited to terminal formulation. Intermediate process streams exposed to concentration, hold and chromatographic separation steps exhibit divergent buffer tolerance profiles. Enveloped VLPs in particular possess extremely narrow stability windows; conventional universal buffers such as standard phosphate-buffered saline (PBS) may trigger severe particle aggregation during long-term storage despite ostensibly mild physicochemical properties.
Notably, buffer design strategies are highly contingent on the adopted manufacturing route. For native-state preservation workflows, buffer conditions are maintained conservatively to retain full structural integrity from cell harvest through final drug substance. Conversely, processes incorporating disassembly–reassembly deploy buffers as active regulatory agents, where controlled shifts in pH, ionic milieu and redox potential guide reversible structural transformation of VLP subunits.
Conclusion
Owing to the inherent structural complexity of VLPs, their purification cannot rely on isolated unit operations alone; instead, CQA-oriented integrated process strategies are mandatory. The overarching objectives are threefold: sustained preservation of structural and biological activity, fine-grained control over product heterogeneity, and comprehensive assurance of drug substance safety. Orthogonal integration of clarification, UF/DF and multi-modal chromatography, complemented by targeted disassembly–reassembly workflows where applicable, enables robust clearance of both host-derived and product-related impurities.
Looking ahead, quality-by-design (QbD)-driven continuous biomanufacturing and process analytical technology (PAT) will substantially elevate process reproducibility and volumetric productivity. Concurrently, evolving regulatory frameworks will establish standardized quality evaluation systems tailored to the unique attributes of VLP therapeutics. Deep mechanistic understanding of target VLP biophysics coupled with flexible deployment of integrated downstream workflows will be the key to overcoming current production bottlenecks and accelerating the clinical translation of high-quality VLP-based biopharmaceuticals.
